| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Iosif Pediaditakis, Konstantia R Kodella, Dimitris V Manatakis, Christopher Y Le, Chris D Hinojosa, William Tien-Street, Elias S Manolakos, Kostas Vekrellis, Geraldine A Hamilton, Lorna Ewart, Lee L Rubin, Katia Karali. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nature communications. vol 12. issue 1. 2021-11-01. PMID:34625559. |
here we leveraged the organs-on-chips technology to develop a human brain-chip representative of the substantia nigra area of the brain containing dopaminergic neurons, astrocytes, microglia, pericytes, and microvascular brain endothelial cells, cultured under fluid flow. |
2021-11-01 |
2023-08-13 |
human |
| A A Kolacheva, M V Ugrumo. A Mouse Model of Nigrostriatal Dopaminergic Axonal Degeneration As a Tool for Testing Neuroprotectors. Acta naturae. vol 13. issue 3. 2021-10-30. PMID:34707903. |
degeneration of nigrostriatal dopaminergic neurons in parkinson's disease begins from the axonal terminals in the striatum and, then, in retrograde fashion, progresses to the cell bodies in the substantia nigra. |
2021-10-30 |
2023-08-13 |
mouse |
| K Ushna S Islam, Norisa Meli, Sandra Blaes. The Development of the Mesoprefrontal Dopaminergic System in Health and Disease. Frontiers in neural circuits. vol 15. 2021-10-30. PMID:34712123. |
midbrain dopaminergic neurons located in the substantia nigra and the ventral tegmental area are the main source of dopamine in the brain. |
2021-10-30 |
2023-08-13 |
Not clear |
| Michelle Ann C Sy, Hubert H Fernande. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD). Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 17. issue 4. 2021-10-28. PMID:32935299. |
the earliest clinical manifestation presents in the middle stage of the disorder pathologically, when 50% or more of the dopaminergic neurons have degenerated in the substantia nigra. |
2021-10-28 |
2023-08-13 |
Not clear |
| Jui-Chih Chang, Yi-Chun Chao, Huei-Shin Chang, Yu-Ling Wu, Hui-Ju Chang, Yong-Shiou Lin, Wen-Ling Cheng, Ta-Tsung Lin, Chin-San Li. Intranasal delivery of mitochondria for treatment of Parkinson's Disease model rats lesioned with 6-hydroxydopamine. Scientific reports. vol 11. issue 1. 2021-10-28. PMID:34011937. |
dopaminergic (da) neuron survival and recovery > 60% occurred in lesions of the substantia nigra (sn) and striatum in mito and p-mito rats. |
2021-10-28 |
2023-08-13 |
rat |
| Malte Brammerloh, Markus Morawski, Isabel Friedrich, Tilo Reinert, Charlotte Lange, Primož Pelicon, Primož Vavpetič, Steffen Jankuhn, Carsten Jäger, Anneke Alkemade, Rawien Balesar, Kerrin Pine, Filippos Gavriilidis, Robert Trampel, Enrico Reimer, Thomas Arendt, Nikolaus Weiskopf, Evgeniya Kirilin. Measuring the iron content of dopaminergic neurons in substantia nigra with MRI relaxometry. NeuroImage. vol 239. 2021-10-28. PMID:34119638. |
measuring the iron content of dopaminergic neurons in substantia nigra with mri relaxometry. |
2021-10-28 |
2023-08-13 |
human |
| Malte Brammerloh, Markus Morawski, Isabel Friedrich, Tilo Reinert, Charlotte Lange, Primož Pelicon, Primož Vavpetič, Steffen Jankuhn, Carsten Jäger, Anneke Alkemade, Rawien Balesar, Kerrin Pine, Filippos Gavriilidis, Robert Trampel, Enrico Reimer, Thomas Arendt, Nikolaus Weiskopf, Evgeniya Kirilin. Measuring the iron content of dopaminergic neurons in substantia nigra with MRI relaxometry. NeuroImage. vol 239. 2021-10-28. PMID:34119638. |
in parkinson's disease, the depletion of iron-rich dopaminergic neurons in nigrosome 1 of the substantia nigra precedes motor symptoms by two decades. |
2021-10-28 |
2023-08-13 |
human |
| Yu-Ling Hsu, Huey-Shan Hung, Chia-Wen Tsai, Shih-Ping Liu, Yu-Ting Chiang, Yun-Hua Kuo, Woei-Cherng Shyu, Shinn-Zong Lin, Ru-Huei F. Peiminine Reduces ARTS-Mediated Degradation of XIAP by Modulating the PINK1/Parkin Pathway to Ameliorate 6-Hydroxydopamine Toxicity and α-Synuclein Accumulation in Parkinson's Disease Models In Vivo and In Vitro. International journal of molecular sciences. vol 22. issue 19. 2021-10-28. PMID:34638579. |
the treatment strategies being developed are based on the typical pathologic features of pd, including the death of dopaminergic (da) neurons in the substantia nigra of the midbrain and the accumulation of α-synuclein in neurons. |
2021-10-28 |
2023-08-13 |
Not clear |
| Fatema Currim, Jyoti Singh, Anjali Shinde, Dhruv Gohel, Milton Roy, Kritarth Singh, Shatakshi Shukla, Minal Mane, Hitesh Vasiyani, Rajesh Sing. Exosome Release Is Modulated by the Mitochondrial-Lysosomal Crosstalk in Parkinson's Disease Stress Conditions. Molecular neurobiology. vol 58. issue 4. 2021-10-27. PMID:33404982. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra (sn) pars compacta region of the brain. |
2021-10-27 |
2023-08-13 |
Not clear |
| Wei He, Mei Jiang, Ping Mao, Fang Ya. TLR4 inhibition ameliorates mesencephalic substantia nigra injury in neonatal rats exposed to lipopolysaccharide via regulation of neuro-immunity. Brain research bulletin. vol 165. 2021-10-26. PMID:32956769. |
the number of dopaminergic neurons in the mesencephalic substantia nigra in septic brain was significantly reduced. |
2021-10-26 |
2023-08-13 |
rat |
| Juan Pérez-Fernández, Marta Barandela, Cecilia Jiménez-Lópe. The Dopaminergic Control of Movement-Evolutionary Considerations. International journal of molecular sciences. vol 22. issue 20. 2021-10-26. PMID:34681941. |
dopamine is likely the most studied modulatory neurotransmitter, in great part due to characteristic motor deficits in parkinson's disease that arise after the degeneration of the dopaminergic neurons in the substantia nigra |
2021-10-26 |
2023-08-13 |
Not clear |
| Alicia M P Warnecke, Moon S Kang, Michael W Jakowec, Daryl L Davie. The macrocyclic lactones ivermectin and moxidectin show differential effects on rotational behavior in the 6-hydroxydopamine mouse model of Parkinson's disease. Behavioural brain research. vol 393. 2021-10-25. PMID:32668263. |
p2 × 4rs are expressed throughout the central nervous system including the dopaminergic circuitry of the substantia nigra, basal ganglia, and related reward networks. |
2021-10-25 |
2023-08-13 |
mouse |
| Lucie Valek, Irmgard Tegede. Failure of Diphtheria Toxin Model to Induce Parkinson-Like Behavior in Mice. International journal of molecular sciences. vol 22. issue 17. 2021-10-25. PMID:34502404. |
the models only partly mimic a predominant loss of dopaminergic neurons in the substantia nigra. |
2021-10-25 |
2023-08-13 |
mouse |
| Susan R Goulding, Jayanth Anantha, Louise M Collins, Aideen M Sullivan, Gerard W O'Keeff. Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease. Neural regeneration research. vol 17. issue 1. 2021-10-22. PMID:34100424. |
the disease is characterized by the progressive loss of midbrain dopaminergic neurons from the substantia nigra, and their axons, which innervate the striatum, resulting in the characteristic motor and non-motor symptoms of parkinson's disease. |
2021-10-22 |
2023-08-13 |
rat |
| Susan R Goulding, Jayanth Anantha, Louise M Collins, Aideen M Sullivan, Gerard W O'Keeff. Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease. Neural regeneration research. vol 17. issue 1. 2021-10-22. PMID:34100424. |
one promising disease-modifying strategy to arrest the loss of dopaminergic neurons is the targeted delivery of neurotrophic factors to the substantia nigra or striatum, to protect the remaining dopaminergic neurons of the nigrostriatal pathway. |
2021-10-22 |
2023-08-13 |
rat |
| Fabin Han, Yanming Liu, Jin Huang, Xiaoping Zhang, Chuanfei We. Current Approaches and Molecular Mechanisms for Directly Reprogramming Fibroblasts Into Neurons and Dopamine Neurons. Frontiers in aging neuroscience. vol 13. 2021-10-22. PMID:34658841. |
parkinson's disease is mainly caused by specific degeneration of dopaminergic neurons (da neurons) in the substantia nigra of the middle brain. |
2021-10-22 |
2023-08-13 |
human |
| Gaia Skibinski, Steven Finkbeine. Drug discovery in Parkinson's disease-Update and developments in the use of cellular models. International journal of high throughput screening. vol 2011. issue 2. 2021-10-21. PMID:23505333. |
parkinson's disease (pd) is the second most common neurodegenerative disorder and is characterized by the degeneration of dopaminergic (da) neurons within the substantia nigra. |
2021-10-21 |
2023-08-12 |
Not clear |
| Louise Oliveira Fiametti, Claudia Neves Correa, Leandro Mantovani de Castr. Peptide Profile of Zebrafish Brain in a 6-OHDA-Induced Parkinson Model. Zebrafish. vol 18. issue 1. 2021-10-21. PMID:33570475. |
parkinson's disease (pd) is a chronic neurodegenerative disorder mainly attributed to the progressive loss of dopaminergic neurons in the substantia nigra, which leads to uncontrolled voluntary movements causing tremors, postural instability, joint stiffness, and speech and locomotion difficulties, among other symptoms. |
2021-10-21 |
2023-08-13 |
zebrafish |
| Yuria Hori, Reiho Tsutsumi, Kento Nasu, Alex Boateng, Yasuhiko Ashikari, Masaharu Sugiura, Makoto Nakajima, Yuki Kurauchi, Akinori Hisatsune, Hiroshi Katsuki, Takahiro Sek. Aromatic-Turmerone Analogs Protect Dopaminergic Neurons in Midbrain Slice Cultures through Their Neuroprotective Activities. Cells. vol 10. issue 5. 2021-10-21. PMID:34063571. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. |
2021-10-21 |
2023-08-13 |
Not clear |
| Xiaoni Xu, Yajun Zhang, Yonggang Kang, Shujuan Liu, Yarong Wang, Yinxia Wang, Lin Wan. LncRNA MIAT Inhibits MPP Neurochemical research. vol 46. issue 12. 2021-10-21. PMID:34514556. |
lncrna miat inhibits mpp parkinson's disease (pd) is an age-related neurodegenerative disease caused by the loss of dopaminergic neurons in the substantia nigra. |
2021-10-21 |
2023-08-13 |
Not clear |